FIGURE 6.
Therapeutic effects of nanoparticles composed of PBAE537 and therapeutic plasmids targeting HPV16 E 7 and p53 K14-HPV16 transgenic mice. (A, B) Representative images of H and E and IHC staining and (C) comparison of the cervical epithelium between untreated HPV16 transgenic mice (control group) and three other targeted groups treated with nanoparticles composed of PBAE537 and plasmids (60:1, 10 μg of plasmids per day for 20 days continuously. IHC staining indicators included HPV16 E 7 , P16, RB1, E2F1, p53, 14-3-3 Sigma, P21, Ki67, and CDK2. Scale bars, 20 μm. The data represent the mean ± SEM (n = 3). One-way ANOVA was used for statistical analysis, *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001, N.S.: no significant difference.